[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cognitive-remediation\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cognitive-remediation":13},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,47],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":31,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100606123","cognitive-remediation-100606123",false,"NCT07171450","Cognitive Remediation","Computerized Cognitive Remediation of Postviral Neurocognitive Dysfunction in Older Adults","Inclusion Criteria:\n\n* age ≥ 60 years old\n* prior history of COVID-19 that was confirmed with viral testing (e.g., positive laboratory test or positive at-home rapid test)\n* cognitive symptoms (e.g., memory or thinking concerns) following COVID- 19 infection that have lasted for at least 12 weeks and are still present\n* clinically meaningfully subjective cognitive concerns (i.e., T-score \\\u003C 40) on the PROMIS-Cognitive Function Scale\n* objective evidence of cognitive decline\\*, as defined by performance on standardized measures of executive functioning, memory, or processing speed from the NIH Toolbox Cognition Battery that is at least 1 standard deviation below estimated premorbid cognitive functioning \\[\\*at least one third of the sample, or 25 out of 75 subjects, will be required to meet this inclusion criterion\\]\n* fluent in English language\n* off psychiatric medication or on a stable dose for at least 8 weeks\n\nExclusion Criteria:\n\n* history of neurological disorder with potential to interfere with study participation or confound results (e.g., uncontrolled seizure disorder, moderate to severe traumatic brain injury or stroke with persistent neurological deficits)\n* history of dementia and\u002For dementia range performance on the Mini- Mental State Examination (i.e., score of less than or equal to 23)\n* prior diagnosis of Mild Cognitive Impairment (MCI) or Mild Neurocognitive Disorder unrelated to the participant's history of COVID-19\n* history of severe psychiatric illness that may interfere with study participation or confound results (e.g., bipolar disorder, schizophrenia, or other psychotic disorder)\n* history of significant neurodevelopmental condition that may interfere with study participation or confound results (e.g., intellectual disability, autism spectrum disorder, or specific learning disorder with impairment in reading)\n* alcohol or other substance use disorder within the past 2 years\n* significant sensory impairments (e.g., blindness) that would interfere with the ability to complete neuropsychological measures or engage in the tablet-based intervention\n* performance that is below expectation on a test of effort and validity","ALL","60 Years",{"count":19,"type":20},75,"ESTIMATED","INTERVENTIONAL",[23],"NA","The goal of this clinical trial is to determine if a neuroscience-based computerized cognitive remediation (\"brain training\") program can treat neurocognitive dysfunction (i.e., memory or thinking difficulties) that emerges in some older adults following a viral infection. The main questions it aims to answer are:\n\n* Does computerized cognitive remediation improve cognitive performance and day-to-day functioning in older adults with postviral neurocognitive dysfunction?\n* Will treatment effects be maintained over time, leading to better long term cognitive outcomes?\n* Does the treatment lead to reductions in blood-based markers of inflammation as a potential mechanism of cognitive symptom improvement?\n* Can the treatment be optimized and refined based on feedback from participants to improve user (patient) experience? Researchers will compare the computerized cognitive remediation program to an active computer-based control condition (alternative computer activities) to see if the computerized cognitive remediation program works to treat postviral neurocognitive dysfunction.\n\nParticipation takes approximately 43-48 hours over 7 months, with most activities (40-46 hours) completed within the first 7-8 weeks, including:\n\n* Initial intake visit: Eligibility confirmation (\\~2-3 hours)\n* Computer activities: About 5 hours per week for \\~6 weeks (total \\~30 hours) completed on a computer tablet provided by the study and loaned to participants for use during the treatment phase\n* Weekly remote check-in meetings: \\~30 minutes each during treatment\n* Blood draws: Two sessions (before and after treatment), \\~20-30 minutes each\n* Three research visits: Pre-treatment, post-treatment, and 6-month follow-up (\\~2-3 hours each, including assessments of cognitive, emotional, and daily functioning)",[26,27,13,28,29,30],"Aging","Inflammation","Cognitive Dysfunction","Postviral Syndrome","Digital Medicine",[26,27,13,32,29,33],"Cognitive dysfunction","digital medicine","RECRUITING","2026-02-20",{"date":37,"type":38},"2026-02-24","ACTUAL",{"date":40,"type":38},"2026-01-21",{"date":42,"type":20},"2030-02-28",{"name":44,"class":45},"Cutter Lindbergh","OTHER",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":16,"minAge":54,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":21,"phases":57,"briefSummary":58,"conditions":59,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":5},"100490571","longitudinal-neurocognitive-psychosocial-and-health-related-quality-of-life-assessment-in-advanced-cancer-survivors-treated-with-immunotherapy-and-the-efficacy-of-integrative-neurocognitive-remediation-therapy-100490571","NCT05667857","Longitudinal Neurocognitive, Psychosocial and Health-related Quality of Life Assessment in Advanced Cancer Survivors Treated With Immunotherapy and the Efficacy of Integrative Neurocognitive Remediation Therapy","CognIT","Inclusion Criteria:\n\n1. Non-intervention group:\n\n   * Provision of written informed consent\n   * Diagnosed with advanced cancer of any type\n   * Initiated immunotherapy (Anti-PD1, Anti-PDL1, CTLA-4, …) at least one year ago\n   * Have a confirmed normalization on whole-body 18F-FDG PET\n   * English, Dutch or French-speaking\n2. Integrative neurocognitive remediation therapy group:\n\n   * Provision of written informed consent\n   * Objective cognitive impairment and\u002For subjective cognitive complaints\n   * Confirmed normalization on whole-body 18F-FDG PET for patients (cohort 1)\n   * Disease-free (cohort 2) or no active disease for patients with CNS tumors (cohort 3)\n   * Having received a cancer therapy of any kind\n   * Having ended cancer treatment (immunotherapy, chemotherapy, radiotherapy, surgery, …) with an exception of ongoing adjuvant hormone therapy\n   * Dutch or French speaking\n\nExclusion Criteria:\n\n* severe co-morbid non cancer-related psychiatric disorders such as psychosis, obsessive compulsive disorders, eating disorders etc., patients with cognitive impairment related to dementia, and patients that are physically or mentally not able to fill in the questionnaires","18 Years",{"count":56,"type":20},100,[23],"Since 2010, the field of immunotherapy has grown substantially, leading to a growing population of long-term cancer survivors treated with immunotherapy. Since cancer survivorship in immunotherapy is an emerging field, to date not much is known about psychosocial and neurocognitive survivorship-related issues in advanced cancer survivors treated with immunotherapy. Preliminary findings indicated significant psychosocial and cognitive problems in survivors of advanced melanoma persist after treatment with immunotherapy. The objective for this project is twofold. First, the investigators want to longitudinally identify survival-related problems in survivors of advanced cancer treated with immunotherapy. The second goal is to identify the efficacy of an Integrative Neuro-Cognitive Remediation Therapy (INCRT) program. The investigators will focus on the following outcomes: (1) Psychosocial consequences, such as emotional complaints, fatigue, fear of recurrence, (2) neurocognitive functioning, and (3) health-related quality of life. The INCRT combines personalized computerized cognitive training and neurocognitive strategy training, with group sessions of exercise, mindfulness, Acceptance and Commitment Therapy, and cognitive behavioral therapy.\n\nWe will have three cohorts:\n\n* Cohort 1: advanced cancer survivors treated with immunotherapy\n* Cohort 2: cancer survivors treated with cancer therapy of any kind (excluded immunotherapy), and who have subjective complaints and\u002For objective cognitive impairment\n* Cohort 3: cancer survivors of a central nervous system (CNS) tumor, who do not have active disease in the CNS, and who have subjective complaints and\u002For objective cognitive impairment\n\nIn the first part of the study, survival-related problems will be evaluated in cohort 1, in a longitudinal manner by means of a semi-structured interview at baseline, various questionnaires and a computerized neuropsychological test battery.\n\nIn the second part of the study, patients of cohort 1, 2 and 3 with subjective or objective cognitive dysfunction can follow the INCRT program. The efficacy of the INCRT is evaluated through a pre-INCRT and post-INCRT evaluation. This evaluation consist of several questionnaires and neuropsychological tests. Long-term efficacy will be evaluated by a follow-up evaluation six months after completion of the INCRT program.",[13,60,61,62,63,64,65,28,66],"Neuropsychology","Quality of Life","Psycho-Oncology","Cognitive Behavioral Therapy","Cancer Survivors","Immunotherapy","Psychological Distress","2025-01-16",{"date":69,"type":38},"2025-01-20",{"date":71,"type":38},"2022-07-13",{"date":73,"type":20},"2033-12",{"name":75,"class":45},"Universitair Ziekenhuis Brussel"]